Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | GAK | O14976 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 7/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | KIF11 | P52732 | 4/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26549449 | 1.00 | ESR2 (0.53) | ESR2GAKPDGFRBPDGFRACA12 | |
| SCHEMBL26549066 | 0.94 | PDGFRB (0.59) | ESR2GAKPDGFRBPDGFRACA12 | |
| SCHEMBL26549457 | 0.94 | GAK (0.48) | ESR2GAKPDGFRBPDGFRACA12 | |
| SCHEMBL26549177 | 0.94 | GAK (0.48) | ESR2GAKPDGFRBPDGFRACA12 | |
| SCHEMBL26550422 | 0.94 | GAK (0.48) | ESR2GAKPDGFRBPDGFRACA12 | |
| SCHEMBL26549359 | 0.94 | PDGFRB (0.59) | ESR2GAKPDGFRBPDGFRACA12 | |
| SCHEMBL26549438 | 0.94 | PDGFRB (0.51) | ESR2GAKPDGFRBPDGFRACA12 | |
| SCHEMBL26549166 | 0.94 | PDGFRB (0.51) | ESR2GAKPDGFRBPDGFRACA12 | |
| SCHEMBL26549445 | 0.94 | PDGFRB (0.51) | ESR2GAKPDGFRBPDGFRACA12 | |
| SCHEMBL26549174 | 0.94 | PDGFRB (0.51) | ESR2GAKPDGFRBPDGFRACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230337527-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | LAPTO CO., LTD. (KR) | 2023-10-19 | — | — | US | disclosed |
| US-20230337527-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | LAPTO CO., LTD. (KR) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230337527-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | AOC1, ODC1, PIEZO1 | ESR2 1164/4885GAK 3896/4885PDGFRB 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.